Meghana Chalasani, Jonathan C Markle, Priya Shukla, Rula A Hajj-Ali, Katherine E Talcott, Rishi P Singh
{"title":"Janus 激酶抑制剂的使用与视网膜静脉闭塞发展之间的关系","authors":"Meghana Chalasani, Jonathan C Markle, Priya Shukla, Rula A Hajj-Ali, Katherine E Talcott, Rishi P Singh","doi":"10.3928/23258160-20240908-01","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Janus kinase (Jak) inhibitors may have increased risk of thromboembolism compared to tumor necrosis factor (TNF) inhibitors. This study investigates the association between Jak inhibitor use and retinal vein occlusion.</p><p><strong>Patients and methods: </strong>This retrospective, non-randomized cohort study used a federated health research network. Propensity-score matched risk ratios with 95% CI were calculated for central and branch retinal vein occlusion (CRVO, BRVO) in patients with immune-mediated inflammatory diseases (IMIDs) treated with Jak inhibitors versus TNF inhibitors.</p><p><strong>Results: </strong>Jak and TNF inhibitor cohorts each had 5,249 patients. Risk ratio for CRVO with Jak inhibitors (<i>n</i> = 11) versus TNF inhibitors (<i>n</i> = 18) was 0.61 [CI (0.29,1.29)]. Risk ratio for BRVO with Jak inhibitors (<i>n</i> = 17) compared to TNF inhibitors (<i>n</i> = 19) was 0.89 [CI (0.47,1.72)].</p><p><strong>Conclusion: </strong>This study did not find evidence of increased risk of RVO with the use of Jak inhibitors compared to TNF inhibitors among patients with IMIDs, contributing to literature on Jak inhibitor safety. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2024;55:xx-xx.]</b>.</p>","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship Between Janus Kinase Inhibitor Use and Development of Retinal Vein Occlusion.\",\"authors\":\"Meghana Chalasani, Jonathan C Markle, Priya Shukla, Rula A Hajj-Ali, Katherine E Talcott, Rishi P Singh\",\"doi\":\"10.3928/23258160-20240908-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Janus kinase (Jak) inhibitors may have increased risk of thromboembolism compared to tumor necrosis factor (TNF) inhibitors. This study investigates the association between Jak inhibitor use and retinal vein occlusion.</p><p><strong>Patients and methods: </strong>This retrospective, non-randomized cohort study used a federated health research network. Propensity-score matched risk ratios with 95% CI were calculated for central and branch retinal vein occlusion (CRVO, BRVO) in patients with immune-mediated inflammatory diseases (IMIDs) treated with Jak inhibitors versus TNF inhibitors.</p><p><strong>Results: </strong>Jak and TNF inhibitor cohorts each had 5,249 patients. Risk ratio for CRVO with Jak inhibitors (<i>n</i> = 11) versus TNF inhibitors (<i>n</i> = 18) was 0.61 [CI (0.29,1.29)]. Risk ratio for BRVO with Jak inhibitors (<i>n</i> = 17) compared to TNF inhibitors (<i>n</i> = 19) was 0.89 [CI (0.47,1.72)].</p><p><strong>Conclusion: </strong>This study did not find evidence of increased risk of RVO with the use of Jak inhibitors compared to TNF inhibitors among patients with IMIDs, contributing to literature on Jak inhibitor safety. <b>[<i>Ophthalmic Surg Lasers Imaging Retina</i> 2024;55:xx-xx.]</b>.</p>\",\"PeriodicalId\":19679,\"journal\":{\"name\":\"Ophthalmic surgery, lasers & imaging retina\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic surgery, lasers & imaging retina\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/23258160-20240908-01\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20240908-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Relationship Between Janus Kinase Inhibitor Use and Development of Retinal Vein Occlusion.
Background and objective: Janus kinase (Jak) inhibitors may have increased risk of thromboembolism compared to tumor necrosis factor (TNF) inhibitors. This study investigates the association between Jak inhibitor use and retinal vein occlusion.
Patients and methods: This retrospective, non-randomized cohort study used a federated health research network. Propensity-score matched risk ratios with 95% CI were calculated for central and branch retinal vein occlusion (CRVO, BRVO) in patients with immune-mediated inflammatory diseases (IMIDs) treated with Jak inhibitors versus TNF inhibitors.
Results: Jak and TNF inhibitor cohorts each had 5,249 patients. Risk ratio for CRVO with Jak inhibitors (n = 11) versus TNF inhibitors (n = 18) was 0.61 [CI (0.29,1.29)]. Risk ratio for BRVO with Jak inhibitors (n = 17) compared to TNF inhibitors (n = 19) was 0.89 [CI (0.47,1.72)].
Conclusion: This study did not find evidence of increased risk of RVO with the use of Jak inhibitors compared to TNF inhibitors among patients with IMIDs, contributing to literature on Jak inhibitor safety. [Ophthalmic Surg Lasers Imaging Retina 2024;55:xx-xx.].
期刊介绍：
OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
